Intesa invests 360 million euros to manage its entire health insurance business

Published Date: 08 Mar 2023

Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.

Read Full News

Todays Updates


FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention Marco Meglio, Isabella Ciccone, MPH


The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.

Consistent TAPS Use Associated With Underlying Tremor Improvement in Essential Tremor Isabella Ciccone, MPH


An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.

New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients Louie Pasculli, Rory Siegel, DO, Julian Bailes, MD


A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.

Recapping MDS 2026: Biomarkers, Aging, and Prodromal Movement Disorders Marco Meglio, Odinachi Oguh, MD


Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.

New York Forum Tackles Unmet Needs in Multiple Sclerosis Care Marco Meglio


At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD


Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control


Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Todays Updates


FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention Marco Meglio, Isabella Ciccone, MPH


The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.

Consistent TAPS Use Associated With Underlying Tremor Improvement in Essential Tremor Isabella Ciccone, MPH


An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.

New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients Louie Pasculli, Rory Siegel, DO, Julian Bailes, MD


A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.

Recapping MDS 2026: Biomarkers, Aging, and Prodromal Movement Disorders Marco Meglio, Odinachi Oguh, MD


Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.

New York Forum Tackles Unmet Needs in Multiple Sclerosis Care Marco Meglio


At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD


Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control


Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New research points out a promising strategy for treating metastatic medulloblastoma

2.

New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

Use of social media during pregnancy may increase depression.

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot